Department of Physical Health and Ageing, Norwegian Institute of Public Health, Oslo, Norway
Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
BMJ Open. 2022 May 2;12(5):e057823. doi: 10.1136/bmjopen-2021-057823.
Patients with hip fracture are typically characterised by extensive comorbidities and excess mortality. Methods that account for a wide range of comorbidities are needed when attempting to identify causal associations in registry-based studies. We aimed to study the association between the prescription-based Rx-Risk Comorbidity Index (abbreviated Rx-Risk) and mortality by history of hip fracture, and to quantify the contribution of Rx-Risk in explaining the excess mortality after hip fracture.
In this prospective study, we used nationwide registry data from outpatient care. Rx-Risk was based on filled prescriptions recorded in the Norwegian Prescription Database. Medications were mapped to 46 comorbidity categories by Anatomical Therapeutic Chemical code. Information on hip fractures during 1994-2013 was available from the Norwegian Epidemiologic Osteoporosis Studies hip fracture database, and year of death was obtained from Statistics Norway. We estimated 1-year mortality risk (January through December 2014) according to Rx-Risk score based on dispensed prescriptions in 2013, history of hip fracture, age and sex using Poisson regression.
All individuals aged 65 years and older who were alive by the end of 2013 and had filled at least one prescription in an outpatient pharmacy in Norway in 2013 (n=735 968).
Mortality increased exponentially with increasing Rx-Risk scores, and it was highest in persons with a history of hip fracture across the major range of Rx-Risk scores. Age- and sex-adjusted mortality risk difference according to history of hip fracture (yes vs no) was 4.4 percentage points (7.8% vs 3.4%). Adjustment for Rx-Risk score further attenuated this risk difference to 3.3 percentage points.
History of hip fracture and comorbidity assessed by Rx-Risk are independent risk factors for mortality in the community-dwelling older population in Norway. Comorbidity explained a quarter of the excess mortality in persons with a history of hip fracture.
髋部骨折患者通常具有广泛的合并症和过高的死亡率。在试图从注册研究中确定因果关系时,需要使用能够考虑到广泛合并症的方法。本研究旨在探讨基于处方的 Rx-Risk 合并症指数(简称 Rx-Risk)与髋部骨折史之间的相关性,并量化 Rx-Risk 对髋部骨折后过度死亡率的解释程度。
本前瞻性研究使用了来自门诊护理的全国性注册数据。Rx-Risk 基于挪威处方数据库中记录的已配药处方。药物按解剖治疗化学代码映射到 46 种合并症类别。1994-2013 年的髋部骨折信息可从挪威骨质疏松症流行病学研究髋部骨折数据库获得,死亡年份可从挪威统计局获得。我们根据 2013 年配药处方、髋部骨折史、年龄和性别,使用泊松回归估计 2014 年 1 年死亡率风险(2014 年 1 月至 12 月)。
2013 年所有年龄在 65 岁及以上、生存且在挪威门诊药房至少配过一次药的个体(n=735968)。
死亡率随 Rx-Risk 评分的增加呈指数增长,在 Rx-Risk 评分的主要范围内,具有髋部骨折史的患者死亡率最高。根据髋部骨折史(是 vs 否),年龄和性别调整后的死亡率差异为 4.4 个百分点(7.8% vs 3.4%)。调整 Rx-Risk 评分后,该风险差异进一步降低至 3.3 个百分点。
在挪威的社区居住的老年人群中,髋部骨折史和 Rx-Risk 评估的合并症是死亡率的独立危险因素。合并症解释了髋部骨折患者过度死亡率的四分之一。